Compare NOMD & ALMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NOMD | ALMR |
|---|---|---|
| Founded | 2014 | N/A |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Laboratory Analytical Instruments |
| Sector | Consumer Staples | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.5B |
| IPO Year | 2015 | 2026 |
| Metric | NOMD | ALMR |
|---|---|---|
| Price | $12.67 | $24.51 |
| Analyst Decision | Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $12.50 | N/A |
| AVG Volume (30 Days) | ★ 1.3M | 226.1K |
| Earning Date | 05-07-2026 | N/A |
| Dividend Yield | ★ 7.11% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.45 | N/A |
| P/E Ratio | $8.38 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.99 | $21.58 |
| 52 Week High | $17.30 | $29.43 |
| Indicator | NOMD | ALMR |
|---|---|---|
| Relative Strength Index (RSI) | 75.26 | 47.32 |
| Support Level | $12.48 | N/A |
| Resistance Level | $13.04 | $28.35 |
| Average True Range (ATR) | 0.36 | 1.96 |
| MACD | 0.03 | -0.31 |
| Stochastic Oscillator | 94.41 | 6.32 |
Nomad Foods Ltd is a packaged foods company that is involved in the business of manufacturing and distributing branded frozen foods in Western Europe. The company manufactures and markets frozen food products such as fish, vegetables, poultry, Ice Cream, and ready meals like pizza. It sells its products through large grocery retailers under the brand Birds Eye in the United Kingdom and Ireland, Findus in Italy, France, Spain, and Iglo in Germany and other continental markets. The company operates through a single segment being Frozen. The majority of the revenue is generated from the United Kingdom.
Alamar Biosciences Inc is a proteomics company engaged in protein detection and analysis. The company has developed its own NULISA (NUcleic Acid Linked Immuno-Sandwich Assay) technology as the foundation of its Precision Proteomics platform enabling the detection and quantification of protein biomarkers in a single sample with ultra-high sensitivity and high specificity, even from very small volumes of biofluid. The company operates in single segment and focuses on developing a good sensitive proteomic liquid biopsy platform and sells instruments, consumables, and services based on this platform to enable early detection of diseases. The products of the company includes NULISAseq Panels, NULISAqpcr Assays, and others.